DrugRisk Update: March Court Records Show Growing Pradaxa Lawsuits

Share Article

The DrugRisk Center is the largest source on the Web for information on prescription drug research, side effects and legal news. Visit http://www.DrugRisk.com

yaz lawsuit
The resource center has added research indicating patients taking newer blood thinners like dabigatran may be 55% more likely to suffer internal bleeding.

The prescription drug safety center DrugRisk.com is announcing updated legal news on the site for patients taking the blood thinner Pradaxa. Recent court records show the number of lawsuits alleging the drug caused internal bleeding injury or death have risen for the month of March*.

DrugRisk provides the latest recalls, safety alerts, research and legal news to those taking popular prescription drugs. The free resource allows visitors to see if others are experiencing similar side effects, avoid potential dangers and decide if they need legal advice.

Pradaxa, which is made by German drug company Boehringer Ingelheim, was approved by the FDA in 2010 to prevent blood clots and strokes in patients with atrial fibrillation. Experts disagree, however, whether it increases risks of internal bleeding.

The resource center has added research indicating patients taking newer blood thinners like dabigatran may be 55% more likely to suffer internal bleeding**. The Institute for Safe Medication Practices has also advised bleeding from Pradaxa could be 5 times as likely to cause death***.

The FDA recently announced it will conduct a new study comparing the safety Pradaxa and the traditional blood thinning medication warfarin****.

Due to the number of families that have filed a Pradaxa lawsuit alleging internal bleeding, cases have been consolidated in a special federal multidistrict litigation court. The case is formally known as MDL No. 2385, IN RE: Pradaxa Product Liability Litigation, Southern District of Illinois.

Now, Drugrisk has learned the latest report from the Judicial Panel on Multidistrict Litigation shows the number of lawsuits filed has risen over 4% in less than a month, from 2,139 in February to 2,226 as of March 13th*.

Anyone who suffered internal bleeding after taking Pradaxa is encouraged to visit DrugRisk.com or speak with a lawyer about their legal options. Due to the complex nature of these cases, DrugRisk only recommends lawyers who have already handled Pradaxa lawsuits.

Visit http://www.DrugRisk.com today for more information on the research, side effects and litigation news related to Pradaxa and other drugs, or to speak with a lawyer.

*JPML, 3/13/14; jpml.uscourts.gov/sites/jpml/files/Pending_MDL_Dockets_By_District-March-13-2014.pdf
**Gastroenterology, July 2013; gastrojournal.org/article/S0016-5085(13)00290-4/fulltext
***Institute for Safe Medication Practices, 1/9/13; ismp.org/quarterwatch/pdfs/2012Q2.pdf
****Forbes, 1/3/14; forbes.com/sites/larryhusten/2014/01/03/fda-plans-new-safety-assessment-of-dabigatran-pradaxa/

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Patient Advocate
+1 888-415-1859
Email >
Visit website